EMEA-002575-PIP01-19 - paediatric investigation plan

BLU-667

Key facts

• Active Substance:
  BLU-667
• Therapeutic area:
  Oncology
• Decision number:
  P/0266/2019
• PIP number:
  EMEA-002575-PIP01-19
• Pharmaceutical form(s):
  Capsule, hard
• Condition(s) / indication(s):
  Treatment of lung cancer (small cell and non-small cell lung cancer)
• Route(s) of administration:
  Oral use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  26/07/2019

Decision

P/0266/2019: EMA decision of 26 July 2019 on the granting of a product specific waiver for BLU-667, (EMEA-002575-PIP01-19)

AdoptedReference Number: EMA/404549/2019